HilleVax Insider Patrick Heron Awarded 17,199 RSUs, No Shares Sold
Rhea-AI Filing Summary
HilleVax, Inc. (HLVX) – Form 4 filing dated 06/25/2025
Non-employee director Patrick J. Heron reported the receipt of 17,199 Restricted Stock Units (RSUs) on 06/23/2025 at a cost basis of $0.00. The award was made under the company’s Non-Employee Director Compensation Program.
- Vesting: 100% on the earlier of (i) 06/23/2026 or (ii) a Change in Control, subject to continued board service.
- Post-transaction direct holdings: 17,199 shares.
- Indirect holdings: 8,535,337 shares held through Frazier Life Sciences X, L.P., for which Mr. Heron shares voting and investment control.
No derivative securities were reported. The filing represents routine director equity compensation rather than open-market activity and does not involve the sale or disposal of shares.
Positive
- Director equity grant strengthens alignment between board member and shareholders through time-based RSUs.
Negative
- None.
Insights
TL;DR: Routine RSU grant aligns director incentives; minimal immediate market impact.
The award of 17,199 RSUs to Director Patrick Heron is standard board compensation and helps align his interests with shareholders. The single-year cliff vesting plus change-in-control trigger is conventional for biotech boards. Importantly, no shares were sold, and the director’s sizable indirect stake (8.5 million shares) remains unchanged, signaling continued long-term exposure. I view the disclosure as governance-neutral with a slight positive bias due to incentive alignment.
TL;DR: Transaction is immaterial to float; neutral for valuation.
The 17,199 RSUs represent a de minimis 0.04% of HLVX’s 43 million share count (latest 10-Q), thus having no dilution concern. Because the units vest over a year or upon a change in control, there is no immediate liquidity event. The large indirect holding through Frazier Life Sciences X underscores existing insider ownership but is unchanged. Overall, the filing does not alter my earnings or valuation model.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 17,199 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The Restricted Stock Units ("RSUs") were granted on June 23, 2025 pursuant to the Registrant's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant's board of directors through such vesting date. The shares reported herein are held of record by Frazier Life Sciences X, L.P. ("FLS X"). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
